AAN 2026 Neurodegeneration Sessions

Migration, Crosslink

📖

AAN 2026 Neurodegeneration Sessions

active

wiki page Created: 2026-04-02T07:20:05 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-events-aan-2026-neurodegeneration-s

📖 Wiki Page

event642 wordssynced 2026-04-02

Dates: April 18-22, 2026 Location: McCormick Place, Chicago, Illinois, USA Organizer: American Academy of Neurology Website: [aanannualmeeting.com](https://www.aan.com/meetings/annual-meeting)

Overview

flowchart TD events_aan_2026_neurodegenerat["AAN 2026 Neurodegeneration Sessions"] style events_aan_2026_neurodegenerat fill:#4fc3f7,stroke:#333,color:#000 events_aan_2026_neur_0["Session Categories"] events_aan_2026_neurodegenerat -->|"includes"| events_aan_2026_neur_0 style events_aan_2026_neur_0 fill:#81c784,stroke:#333,color:#000 events_aan_2026_neur_1["Scientific Sessions"] events_aan_2026_neurodegenerat -->|"includes"| events_aan_2026_neur_1 style events_aan_2026_neur_1 fill:#ef5350,stroke:#333,color:#000 events_aan_2026_neur_2["Education Sessions"] events_aan_2026_neurodegenerat -->|"includes"| events_aan_2026_neur_2 style events_aan_2026_neur_2 fill:#ffd54f,stroke:#333,color:#000 events_aan_2026_neur_3["Key Research Themes"] events_aan_2026_neurodegenerat -->|"includes"| events_aan_2026_neur_3 style events_aan_2026_neur_3 fill:#ce93d8,stroke:#333,color:#000 events_aan_2026_neur_4["1. Protein Aggregation Mechanisms"] events_aan_2026_neurodegenerat -->|"includes"| events_aan_2026_neur_4 style events_aan_2026_neur_4 fill:#4fc3f7,stroke:#333,color:#000 events_aan_2026_neur_5["2. Neuroinflammation"] events_aan_2026_neurodegenerat -->|"includes"| events_aan_2026_neur_5 style events_aan_2026_neur_5 fill:#81c784,stroke:#333,color:#000

...

Dates: April 18-22, 2026 Location: McCormick Place, Chicago, Illinois, USA Organizer: American Academy of Neurology Website: [aanannualmeeting.com](https://www.aan.com/meetings/annual-meeting)

Overview

Mermaid diagram (expand to render)

The neurodegeneration track at AAN 2026 showcases the latest advances in understanding and treating neurodegenerative diseases. Sessions focus on mechanisms, biomarkers, and therapeutic approaches for Alzheimer's disease, Parkinson's disease, and related disorders.

Session Categories

Scientific Sessions

Platform Presentations

Key platform sessions covering original research:

Alzheimer's Disease Mechanisms: Amyloid, tau, and neuroinflammation
Parkinson's Disease: Alpha-synuclein, LRRK2, and GBA
Frontotemporal Dementia: TARDBP, C9orf72, and tau
Amyotrophic Lateral Sclerosis: SOD1, TDP-43 pathology
Huntington's Disease: Huntingtin and gene therapy

Poster Sessions

Interactive presentations:

Biomarker Studies: Blood, CSF, and imaging
Clinical Outcomes: Functional assessments
Therapeutic Trials: Phase 1-3 results

Education Sessions

Clinical Updates

Diagnostic Criteria: NIA-AA, MDS criteria
Management Guidelines: Best practices
Case Discussions: Challenging presentations

Hands-on Workshops

Biomarker Interpretation: Clinical application
Neuropsychological Assessment: Cognitive testing
Movement Disorders: Clinical examination

Key Research Themes

1. Protein Aggregation Mechanisms

Amyloid Biology

Amyloid-beta oligomerization: Toxic species identification
ARIA: Mechanisms and management
Amyloid clearance: Cellular and molecular pathways[@hodecker2023]

Tau Pathology

Tau phosphorylation: Kinases and phosphatases
Tau spreading: Prion-like propagation
Tau modifications: Acetylation, truncation

Alpha-Synuclein

Oligomer formation: Toxic mechanisms
Cell-to-cell transmission: Spreading mechanisms
Strain diversity: Clinical correlations

2. Neuroinflammation

Microglial Biology

Disease-associated microglia (DAM): Activation states
TREM2 biology: Genetic risk and function
CSF1R inhibition: Microglial modulation[@sankowski2019]

Complement System

Synaptic pruning: C1q and C3 roles
Inflammasome activation: NLRP3 signaling
Therapeutic targeting: Complement inhibition

Astrocyte Reactivity

A1/A2 phenotypes: Functional consequences
Blood-brain barrier: Astrocyte-endothelial interactions
Neurotoxic astrocytes: Mechanisms and targets

3. Biomarker Development

Fluid Biomarkers

Blood-based biomarkers: p-tau217, NfL, GFAP
CSF biomarkers: Core AD markers
Emerging markers: Novel analytes

Imaging Biomarkers

Amyloid PET: Centiloid standardization
Tau PET: Regional quantification
FDG PET: Metabolic patterns

4. Therapeutic Approaches

Disease-Modifying Therapies

Anti-amyloid antibodies: Lecanemab, donanemab
Anti-tau approaches: Immunotherapies, small molecules
Alpha-synuclein targeting: Immunotherapies

Symptomatic Therapies

Cognitive enhancement: Cholinergic approaches
Motor symptoms: Dopaminergic therapies
Non-motor symptoms: Multi-disciplinary management

Neuroprotective Strategies

Synaptic preservation: Functional protection
Metabolic support: Mitochondrial function
Oxidative stress: Antioxidant approaches

Featured Sessions

Plenary Presentations

Presidential Lecture: Future of neurodegeneration research
Keynote Address: Integration of mechanisms
Late-Breaking Science: Recent trial results

Special Symposia

Neurodegeneration Summit: Cross-disease perspectives
Biomarker Integration: Clinical practice
Therapeutic Development: Pipeline overview

Career Development

Early Career Neurology: Research training
Mentorship Programs: Junior investigator guidance
Grant Writing: NIH funding strategies

Cross-Disease Topics

Shared Mechanisms

Protein aggregation: Common therapeutic targets
Neuroinflammation: Microglial involvement
Oxidative stress: Mitochondrial dysfunction
Autophagy: Protein clearance systems

Biomarker Commonalities

NfL: Cross-disease neurodegeneration marker
Neuroinflammation: Shared inflammatory markers
Imaging: Common imaging paradigms

Therapeutic Crossovers

Immunotherapies: Platform approaches
Gene therapy: Common targets
Small molecules: Multi-disease potential

Clinical Applications

Diagnostic Integration

Biomarker-guided diagnosis: AT(N) framework
Clinical criteria: Integration with biomarkers
Differential diagnosis: Cross-disease distinction

Treatment Selection

Personalized medicine: Genetic and biomarker typing
Combination therapies: Multi-target strategies
Monitoring: Biomarker-guided follow-up

Patient Management

Multidisciplinary care: Team approaches
Supportive care: Quality of life
Caregiver support: Family interventions

[AAN 2026](/events/aan-2026) — Main conference page
[AAN 2026 Alzheimer's and Parkinson's Updates](/events/aan-2026-alzheimers-parkinsons-updates)
[AAN 2026 Clinical Trials](/events/aan-2026-clinical-trials)
[AAN 2026 Blood Biomarkers](/events/aan-2026-blood-biomarkers)
[AAIC 2026 Neuroinflammation](/events/aaic-2026-neuroinflammation)

Mechanisms

[Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade)
[Tau Pathology](/mechanisms/tau-pathology)
[Neuroinflammation Pathway](/mechanisms/neuroinflammation)
[Alpha-Synuclein Pathway](/mechanisms/alpha-synuclein-pathology)

Diseases

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Frontotemporal Dementia](/diseases/frontotemporal-dementia)
[Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)

Therapeutic Approaches

[Anti-Amyloid Therapies](/therapeutics/anti-amyloid-therapies)
[Anti-Tau Therapies](/therapeutics/anti-tau-therapies)
[Parkinson's Disease Therapeutics](/therapeutics/parkinsons-therapeutics)

References

[AAN 2026 Annual Meeting](https://www.aan.com/meetings/annual-meeting)

[Hodecker et al., Amyloid-related imaging abnormalities (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[Sankowski et al., Microglial activation states (2019)](https://pubmed.ncbi.nlm.nih.gov/31740912/)

[Neurodegeneration Research](https://pubmed.ncbi.nlm.nih.gov/)

📖 View canonical wiki page →

Related Entities

events-aan-2026-neurodegeneration-sessions

▸Metadataorigin_type: v1_polymorphic_backfill

slug	events-aan-2026-neurodegeneration-sessions
kg_node_id	None
entity_type	event
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-38ab9c9606b7
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'events-aan-2026-neurodegeneration-sessions'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

545

Outgoing

711

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

AAN 2026 Neurodegeneration Sessions

Overview

Overview

Session Categories

Scientific Sessions

Platform Presentations

Poster Sessions

Education Sessions

Clinical Updates

Hands-on Workshops

Key Research Themes

1. Protein Aggregation Mechanisms

Amyloid Biology

Tau Pathology

Alpha-Synuclein

2. Neuroinflammation

Microglial Biology

Complement System

Astrocyte Reactivity

3. Biomarker Development

Fluid Biomarkers

Imaging Biomarkers

4. Therapeutic Approaches

Disease-Modifying Therapies

Symptomatic Therapies

Neuroprotective Strategies

Featured Sessions

Plenary Presentations

Special Symposia

Career Development

Cross-Disease Topics

Shared Mechanisms

Biomarker Commonalities

Therapeutic Crossovers

Clinical Applications

Diagnostic Integration

Treatment Selection

Patient Management

Related Conference Content

Related NeuroWiki Content

Mechanisms

Diseases

Therapeutic Approaches

References

💬 Discussion